On Tuesday, Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was 26.47% up from the session before settling in for the closing price of $16.51. A 52-week range for TEVA has been $10.00 – $19.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -2.68%. When this article was written, the company’s average yearly earnings per share was at -3.17%. With a float of $1.13 billion, this company’s outstanding shares have now reached $1.13 billion.
The extent of productivity of a business whose workforce counts for 37226 workers is very important to gauge. In terms of profitability, gross margin is 49.87%, operating margin of 12.76%, and the pretax margin is -3.36%.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Teva- Pharmaceutical Industries Ltd. ADR stocks. The insider ownership of Teva- Pharmaceutical Industries Ltd. ADR is 0.01%, while institutional ownership is 56.88%. The most recent insider transaction that took place on Nov 20 ’24, was worth 327,085. In this transaction EVP, Head of U.S. Commercial of this company sold 19,388 shares at a rate of $16.87, taking the stock ownership to the 44,104 shares. Before that another transaction happened on Nov 20 ’24, when Company’s Officer proposed sale 19,388 for $16.87, making the entire transaction worth $327,085.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.04% during the next five years compared to 26.63% growth over the previous five years of trading.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators
You can see what Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.41. Likewise, its price to free cash flow for the trailing twelve months is 8.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.85, a number that is poised to hit 0.70 in the next quarter and is forecasted to reach 2.81 in one year’s time.
Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
The latest stats from [Teva- Pharmaceutical Industries Ltd. ADR, TEVA] show that its last 5-days average volume of 18.06 million was superior to 9.35 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 40.67%. Additionally, its Average True Range was 0.83.
During the past 100 days, Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) raw stochastic average was set at 96.76%, which indicates a significant increase from 96.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.17% in the past 14 days, which was higher than the 48.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.56, while its 200-day Moving Average is $16.51. Now, the first resistance to watch is $21.61. This is followed by the second major resistance level at $22.34. The third major resistance level sits at $23.63. If the price goes on to break the first support level at $19.59, it is likely to go to the next support level at $18.30. Assuming the price breaks the second support level, the third support level stands at $17.57.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Key Stats
There are 1,132,909K outstanding shares of the company, which has a market capitalization of 23.69 billion. As of now, sales total 15,846 M while income totals -559,000 K. Its latest quarter income was 4,332 M while its last quarter net income were -437,000 K.
